Literature DB >> 25692853

Efficacy of Rapamycin in Tuberous Sclerosis-Associated Hypopigmented Macules: Back to the Future.

Jack L Arbiser1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25692853      PMCID： PMC4496252          DOI： 10.1001/jamadermatol.2014.4299

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN： 2168-6068            Impact factor:   10.282


× No keyword cloud information.
  6 in total

1.  Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis.

Authors:  Anna K Haemel; Amy L O'Brian; Joyce M Teng
Journal:  Arch Dermatol       Date:  2010-07

2.  White leaf-shaped macules. Earliest visible sign of tuberous sclerosis.

Authors:  T B Fitzpatrick; G Szabó; Y Hori; A A Simone; W B Reed; M H Greenberg
Journal:  Arch Dermatol       Date:  1968-07

3.  Clinical and Histologic Analysis of the Efficacy of Topical Rapamycin Therapy Against Hypomelanotic Macules in Tuberous Sclerosis Complex.

Authors:  Mari Wataya-Kaneda; Mari Tanaka; Lingli Yang; Fei Yang; Daisuke Tsuruta; Ayumi Nakamura; Shoji Matsumoto; Toshimitsu Hamasaki; Atushi Tanemura; Ichiro Katayama
Journal:  JAMA Dermatol       Date:  2015-07       Impact factor: 10.282

4.  Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins.

Authors:  Yong Zhang; Xinsheng Gao; Leslie J Saucedo; Binggen Ru; Bruce A Edgar; Duojia Pan
Journal:  Nat Cell Biol       Date:  2003-06       Impact factor: 28.824

5.  Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.

Authors:  John J Bissler; Francis X McCormack; Lisa R Young; Jean M Elwing; Gail Chuck; Jennifer M Leonard; Vincent J Schmithorst; Tal Laor; Alan S Brody; Judy Bean; Shelia Salisbury; David N Franz
Journal:  N Engl J Med       Date:  2008-01-10       Impact factor: 91.245

6.  A quantitative increase in regulatory T cells controls development of vitiligo.

Authors:  Shilpak Chatterjee; Jonathan M Eby; Amir A Al-Khami; Myroslawa Soloshchenko; Hee-Kap Kang; Navtej Kaur; Osama S Naga; Anuradha Murali; Michael I Nishimura; I Caroline Le Poole; Shikhar Mehrotra
Journal:  J Invest Dermatol       Date:  2013-12-23       Impact factor: 8.551
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.